1,050
Views
0
CrossRef citations to date
0
Altmetric
Oncology

Cost-effectiveness of axicabtagene ciloleucel versus tisagenlecleucel for the treatment of 3L + relapsed/refractory large B-cell lymphoma in the United States: incorporating longer survival results

ORCID Icon, , , , , & ORCID Icon show all
Pages 230-239 | Received 23 Nov 2023, Accepted 11 Jan 2024, Published online: 13 Feb 2024